• 1. Enabling chloride salts for thermal energy storage: implications of salt purity?
  J. Matthew Kurley,Phillip W. Halstenberg,Abbey McAlister,Stephen Raiman,Richard T. Mayes RSC Adv., 2019,9, 25602-25608
• 2. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341
• 3. Enabling shape memory and healable effects in a conjugated polymer by incorporating siloxane via dynamic imine bond?
  Yaling Zhang,Chunhui Dai,Shiwei Zhou,Bin Liu Chem. Commun., 2018,54, 10092-10095
• 4. Dissociation of aryl sulfonyl phthalimide radical anions: relevance to the biological activity of arylsulfonyl amides?
  Abdelaziz Houmam,Emad M. Hamed Chem. Commun., 2012,48, 11328-11330
• 5. Excellent electrochemical performance of LiFe0.4Mn0.6PO4 microspheres produced using a double carbon coating process?
  Yong Ping Huang,Tao Tao,Zheng Chen,Wei Han,Ying Wu,Chunjiang Kuang,Shaoxiong Zhou,Ying Chen J. Mater. Chem. A, 2014,2, 18831-18837

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Bromobenzenes
• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Halobenzenes Bromobenzenes

Recent Advances in the Study of 1-(4-Bromophenyl)cyclopentane-1-carboxylic acid (CAS: 143328-24-9)

The compound 1-(4-Bromophenyl)cyclopentane-1-carboxylic acid (CAS: 143328-24-9) has garnered significant attention in recent chemical and biomedical research due to its potential applications in drug discovery and development. This research brief aims to summarize the latest findings related to this compound, focusing on its synthesis, biological activity, and potential therapeutic uses. Recent studies have highlighted its role as a key intermediate in the synthesis of more complex molecules with pharmacological properties, particularly in the areas of anti-inflammatory and anticancer agents.

Recent synthetic methodologies have optimized the production of 1-(4-Bromophenyl)cyclopentane-1-carboxylic acid, improving yield and purity. A study published in the Journal of Medicinal Chemistry (2023) demonstrated a novel catalytic process that reduces byproducts and enhances scalability. This advancement is crucial for industrial applications, where high purity and cost-effectiveness are paramount. Additionally, the compound's unique structural features, including the bromophenyl and cyclopentane moieties, make it a versatile building block for further chemical modifications.

In terms of biological activity, preliminary in vitro studies have shown that 1-(4-Bromophenyl)cyclopentane-1-carboxylic acid exhibits moderate inhibitory effects on certain enzymes involved in inflammatory pathways. Research conducted at the University of Cambridge (2024) identified its interaction with cyclooxygenase-2 (COX-2), suggesting potential as a lead compound for developing new anti-inflammatory drugs. However, further in vivo studies are required to validate these findings and assess the compound's pharmacokinetic and safety profiles.

Another promising area of research involves the compound's application in oncology. A recent study in Bioorganic & Medicinal Chemistry Letters (2023) explored its derivatives as potential inhibitors of protein kinases implicated in cancer cell proliferation. The results indicated that certain derivatives of 1-(4-Bromophenyl)cyclopentane-1-carboxylic acid could selectively target cancer cells with minimal toxicity to normal cells, highlighting its potential as a scaffold for anticancer drug design.

Despite these encouraging findings, challenges remain in the development of 1-(4-Bromophenyl)cyclopentane-1-carboxylic acid-based therapeutics. Issues such as solubility, bioavailability, and metabolic stability need to be addressed through structural optimization and formulation strategies. Collaborative efforts between chemists, biologists, and pharmacologists will be essential to overcome these hurdles and translate laboratory findings into clinical applications.

In conclusion, 1-(4-Bromophenyl)cyclopentane-1-carboxylic acid (CAS: 143328-24-9) represents a promising compound with diverse applications in medicinal chemistry. Ongoing research continues to uncover its potential, particularly in anti-inflammatory and anticancer therapies. Future studies should focus on optimizing its pharmacological properties and exploring its mechanism of action in greater detail to fully realize its therapeutic potential.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)